Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. (HIMS) reported that Chief Legal Officer Soleil Boughton sold 3,458 shares of Class A Common Stock on September 2, 2026 at $28.33 per share in an open-market or private transaction. After this sale, Boughton directly holds 310,506 shares, and the sale was executed under a Rule 10b5-1 trading plan adopted on May 21, 2026.
Hims & Hers Health, Inc. (HIMS) is named as the issuer in a notice that Soleil Boughton, through Fidelity Brokerage Services LLC, may sell 3,458 Class A shares under Rule 144. These shares relate to restricted stock vesting on August 15, 2026. The form also lists prior sales of 25,111 Class A shares in the past three months.
Hims & Hers Health, Inc. (HIMS) is reporting an updated ownership position for its Chief Executive Officer and director, Andrew Dudum22,610,002 shares tied to the company’s equity structure, representing 9.4% of the Class A common stock on an as-converted, option-exercised basis, and 100% of the outstanding Class V common stock.
The position includes 7,200,015 Class A shares held by affiliated trusts, 1,033,177 Class A shares held directly, 8,377,623 Class V shares held by affiliated trusts, and options for 5,976,847 Class A shares exercisable within 60 days plus 22,340 additional options vesting over four years. Class V shares automatically convert into Class A shares upon certain transfers or board actions. Restricted stock units covering 1,071,690 Class A shares are excluded because they are not expected to settle within 60 days.
Hims & Hers Health, Inc. (HIMS) reported that Chief Executive Officer and director Andrew Dudum made indirect transfers of Class A Common Stock tied to estate planning. On 2026-08-27, a trust associated with him completed a code J transaction distributing 977,566 shares pro rata to its beneficiaries for bona fide estate planning purposes, with no consideration received. On 2026-08-25, a trust associated with him made a code G bona fide gift of 463,289 shares, also for no consideration. Following these transactions, Dudum continues to hold shares both directly and indirectly through multiple trusts.
Hims & Hers Health, Inc. (HIMS) reported an insider transaction by director and Chief Policy Officer Deborah M. Autor. On August 18, 2026, she sold 16,773 shares of Class A Common Stock at $27.85 per share in an open-market or private transaction pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026, and now holds 48,961 shares directly.
Hims & Hers Health, Inc. (HIMS) reported that Chief Financial Officer Oluyemi Okupe exercised stock options for 4,938 shares of Class A Common Stock at an exercise price of $5.0100 per share and on the same date sold 4,938 shares at a weighted average price of $29.9942 per share. The option exercise and related sale were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe held 80,872 stock options directly and 7,853 shares of Class A Common Stock indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. (HIMS) reported that Chief Legal Officer Soleil Boughton sold 25,111 shares of Class A Common Stock on August 19, 2026 at $27.55 per share. The sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2026, and Boughton now directly holds 313,964 shares.
Hims & Hers Health, Inc. (HIMS) received a notice that Soleil Boughton, an officer, intends to sell 25,111 shares of Class A common stock under Rule 144. The shares are held at Fidelity Brokerage Services LLC and relate to restricted stock awards scheduled to vest in 2025 and 2026.
The planned sale amount corresponds to restricted stock vesting of 2,707 shares on June 15, 2025, 18,946 shares on June 15, 2026, and 3,458 shares on August 15, 2026. As of this notice, Class A shares outstanding are reported as 224,935,790.
Hims & Hers Health, Inc. (HIMS) reported equity compensation activity for Chief Legal Officer Soleil Boughton. On 2026-08-14, several tranches of Restricted Stock Units were converted into a total of 42,261 shares of Class A Common Stock at no cash exercise price. In connection with this RSU vesting and settlement, 21,500 shares were withheld by the issuer to satisfy tax withholding obligations at a price of $28.15 per share. The RSUs each represent the right to receive one share of Class A Common Stock and are subject to a 4-year service-based vesting schedule, vesting in substantially equal quarterly installments starting on different dates from June 15, 2023 through June 15, 2026.
Hims & Hers Health, Inc. (HIMS) director Kare Schultz reported the vesting and settlement of restricted stock units into Class A Common Stock. On 2026-08-14, 6,623 RSUs converted into 6,623 shares, increasing direct holdings to 26,020 shares. The RSUs were granted at no cash exercise price and, per the award terms, vest in three substantially equal installments over three years of continuous board service.